GlassScriptPhysician profile
Sung Tae Kim
NPI 1841424074
$2,202.84
in general payments reported to CMS, 2019-2025
21 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2021: $238 · 2022: $157 · 2023: $427 · 2024: $592 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $377.08 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $317.33 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $305.17 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $227.44 | 2023-2025 | |
| Pfizer INC. | $137.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $116.59 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $107.51 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $104.36 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $77.35 | 2023 | Quviviq |
| Abbott Laboratories | $70.74 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $58.43 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.66 | 2024-2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Biotronik Nro, INC. | $51.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $45.18 | 2020-2024 | Strensiq |
| Kowa Pharmaceuticals America, INC. | $38.14 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $25.35 | 2021 | |
| Dexcom, INC. | $24.60 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $17.31 | 2025 | Repatha |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $14.80 | 2023 | Kristalose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.